This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirata, T. Articles by Hidaka, T. Search for Related Content PubMed PubMed Citation Articles by Hirata, T. Articles by Hidaka, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Oct 1995, 2295-2303, Vol 39, No. 10
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

T Hirata, H Saito, H Tomioka, K Sato, J Jidoi, K Hosoe and T Hidaka
Department of Microbiology and Immunology, Shimane Medical University, Izumo, Japan.

The in vitro and in vivo activities of a new benzoxazinorifamycin, KRM- 1648 (KRM), against Mycobacterium tuberculosis were studied. The MIC at which 50% of the isolates are inhibited (MIC50) and the MIC90 of KRM for 30 fresh isolates of M. tuberculosis measured by the BACTEC 460 TB System were 0.016 and 2 micrograms/ml, respectively. These values were much lower than those for rifampin (RMP), which were 4 and >128 micrograms/ml, respectively, and considerably lower than those for rifabutin (RBT), which were 0.125 and 8 micrograms/ml, respectively. A correlational analysis of the MICs of these drugs for the clinical isolates revealed the presence of cross-resistance of the organisms to KRM and either RMP or RBT although the MICs of KRM were distributed over a much lower range than were those of the other two drugs. KRM and RMP at concentrations of 1 to 10 micrograms/ml almost completely inhibited the bacterial growth of RMP-sensitive strains (H37Rv, Kurono, and Fujii) of M. tuberculosis phagocytosed in macrophage-derived J774.1 cells. KRM was more active than RMP in inhibiting the growth of the RMP- resistant (MIC = 8 micrograms/ml) Kurata strain but failed to show such an effect against the RMP-resistant (MIC >128 micrograms/ml) Watanabe stain. When KRM was given to M. tuberculosis-infected mice at dosages of 5 to 20 mg/kg of body weight by gavage, one daily six times per week from day 1 after infection, it was much more efficacious than RMP against infections induced in mice by the RMP-sensitive Kurono strain, as measured by a reduction of rates of mortality, a reduction of the frequency and extent of gross lung lesions, histopathological changes in lung tissues, and a decrease in the bacterial loads in the lungs and spleens of infected mice. KRM also displayed significant therapeutic efficacy against infection induced by the RMP-resistant Kurata strain, while neither KRM nor RMP was efficacious against infection by the RMP- resistant Watanabe strain. In the case of infection with the Kurono strain, the efficacy of the drugs in prolonging the time of survival was in the order KRM, RBT, RMP. KRM was much more efficacious than RMP, when given at 1- to 4-week intervals. These findings suggest that KRM may be useful for the clinical treatment of tuberculosis contracted through RMP-sensitive strains, even when it is administered at long intervals.

This article has been cited by other articles:

• Verma, R. K., Kaur, J., Kumar, K., Yadav, A. B., Misra, A. (2008). Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice. Antimicrob. Agents Chemother. 52: 3195-3201 [Abstract] [Full Text]  
• Rothstein, D. M., Farquhar, R. S., Sirokman, K., Sondergaard, K. L., Hazlett, C., Doye, A. A., Gwathmey, J. K., Mullin, S., van Duzer, J., Murphy, C. K. (2006). Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection. Antimicrob. Agents Chemother. 50: 3658-3664 [Abstract] [Full Text]  
• Anton, P. M., O'Brien, M., Kokkotou, E., Eisenstein, B., Michaelis, A., Rothstein, D., Paraschos, S., Kelly, C. P., Pothoulakis, C. (2004). Rifalazil Treats and Prevents Relapse of Clostridium difficile-Associated Diarrhea in Hamsters. Antimicrob. Agents Chemother. 48: 3975-3979 [Abstract] [Full Text]  
• De Logu, A., Onnis, V., Saddi, B., Congiu, C., Schivo, M. L., Cocco, M. T. (2002). Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 49: 275-282 [Abstract] [Full Text]  
• Dietze, R., Teixeira, L., Rocha, L. M. C., Palaci, M., Johnson, J. L., Wells, C., Rose, L., Eisenach, K., Ellner, J. J. (2001). Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 45: 1972-1976 [Abstract] [Full Text]  
• Brooks, J. V., Orme, I. M. (1998). Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model. Antimicrob. Agents Chemother. 42: 3047-3048 [Abstract] [Full Text]